Short answer
No single THC strain treats pain better than another. Research supports THC for chronic pain. Research does not support one cultivar over another. Product form matters more than strain name. A capsule, tincture, or gummy with a labeled milligram dose gives a repeatable result. A joint does not.
What THC does
THC binds CB1 receptors in the brain and spinal cord. It binds CB2 receptors on immune cells. CB1 activation changes pain signaling. A 2017 review by the National Academies of Sciences, Engineering, and Medicine found substantial evidence that cannabis reduces chronic pain in adults. The same review found limited evidence for most other conditions.
best medical marijuana strains for pain
THC is a partial agonist at both receptors. It produces a weaker response than a full agonist at the same site. That limits the relief from a given dose and adds sedation at high doses.
best cannabis strains for pain management
Cultivars sold for pain
Strain names are marketing labels. Two batches with the same name can carry different cannabinoid and terpene profiles. Labs in legal states test for THC, CBD, and terpenes. Ask for the certificate of analysis.
best cannabis strains for chronic pain 2025
High-THC cultivars
- Northern Lights: indica, often 16% to 21% THC
- OG Kush: hybrid, often 18% to 24% THC
- Bubba Kush: indica, often 15% to 22% THC
- Granddaddy Purple: indica, often 17% to 23% THC
THC with CBD
- Harlequin: often 5% to 10% THC, 8% to 16% CBD
- Cannatonic: often 4% to 10% THC, 8% to 15% CBD
- ACDC: often under 1% THC, 15% to 20% CBD
CBD has low affinity for CB1. It can change how THC acts at the receptor. Human trials on THC to CBD ratios for pain are small and short.
Dose and product form
Oral THC onset runs 30 to 90 minutes. Inhaled THC onset runs 5 to 10 minutes. Oral bioavailability is about 6% to 20%. Inhaled bioavailability is about 10% to 25%.
Manufactured products carry a milligram label. A 5 mg gummy is 5 mg. Flower is not a fixed dose. That gap explains why capsules, tinctures, and gummies took shelf space from flower in states with legal sales.
Start at 1 mg to 2.5 mg THC. Wait two hours before a second dose. Raise the dose by 1 mg to 2.5 mg per step.
Limits of the evidence
Most trials use nabiximols, an oral spray with THC and CBD in a 1:1 ratio. Few trials test smoked flower. Cochrane reviews rate the neuropathic pain evidence as low quality. Sample sizes are small and study runs are short.
Risks
- Impaired driving and slower reaction time for 4 to 6 hours after inhaling
- Dizziness, dry mouth, fast heart rate
- Dependence in about 9% of adults who use cannabis, with higher rates among daily users
- Higher risk above age 65, with heart disease, or during pregnancy
The FDA has not approved cannabis flower for any condition. It has approved dronabinol and nabilone, both synthetic THC products, for chemotherapy-induced nausea.